Literature DB >> 11129129

Management of type 2 diabetes mellitus and cardiovascular risk: lessons from intervention trials.

H Yki-Järvinen1.   

Abstract

Although the diagnosis of type 2 (noninsulin-dependent) diabetes mellitus is made when blood glucose levels exceed values which increase the risk of microvascular complications, macrovascular disease is the major complication of type 2 diabetes mellitus. Both epidemiological and prospective data have demonstrated that treatment of hyperglycaemia is markedly effective in reducing the risk of microvascular disease but is less potent in reducing that of myocardial infarction, stroke and peripheral vascular disease. Treatment of other cardiovascular risk factors, although by definition less prevalent than hyperglycaemia, appears to be more effective in preventing macrovascular disease than treatment of hyperglycaemia. In recent years, data from intervention trials have suggested that greater benefits with respect to the prevention of macrovascular disease can be achieved by effective treatment of hypertension and hypercholesterolaemia, and by the use of small doses of aspirin (acetylsalicylic acid) than by treating hyperglycaemia alone. On the other hand, the UK Prospective Diabetes Study (UKPDS), which examined the impact of intensive glucose and blood pressure (BP) control on micro- and macrovascular complications, is the only intervention trial to include only patients with type 2 diabetes mellitus. The UKPDS data, the epidemic increase in the number of patients with type 2 diabetes mellitus and their high cardiovascular risk have, however, initiated several new trials addressing, in particular, the possible benefits of treatment of the most common form of dyslipidaemia (high serum triglyceride and low high density lipoprotein cholesterol levels) in these patients. Type 2 diabetes mellitus is thus a disease associated with a high vascular risk, where the majority of patients need, and are likely to benefit from, pharmacological treatment of several cardiovascular risk factors provided treatment targets have not been achieved by life-style modification.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11129129     DOI: 10.2165/00003495-200060050-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   11.431


  59 in total

Review 1.  Role of fibrates in the management of hypertriglyceridemia.

Authors:  D J Rader; S M Haffner
Journal:  Am J Cardiol       Date:  1999-05-13       Impact factor: 2.778

2.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.

Authors:  L Hansson; L H Lindholm; L Niskanen; J Lanke; T Hedner; A Niklason; K Luomanmäki; B Dahlöf; U de Faire; C Mörlin; B E Karlberg; P O Wester; J E Björck
Journal:  Lancet       Date:  1999-02-20       Impact factor: 79.321

3.  Glycemic control in patients with diabetes in Finland.

Authors:  T Valle; V A Koivisto; A Reunanen; T Kangas; A Rissanen
Journal:  Diabetes Care       Date:  1999-04       Impact factor: 19.112

4.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

Authors:  M H Frick; O Elo; K Haapa; O P Heinonen; P Heinsalmi; P Helo; J K Huttunen; P Kaitaniemi; P Koskinen; V Manninen
Journal:  N Engl J Med       Date:  1987-11-12       Impact factor: 91.245

Review 5.  Hyperglycemia and cardiovascular disease in type 2 diabetes.

Authors:  M Laakso
Journal:  Diabetes       Date:  1999-05       Impact factor: 9.461

6.  Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group.

Authors: 
Journal:  BMJ       Date:  1998-09-12

7.  Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study.

Authors:  G Zuanetti; R Latini; A P Maggioni; M Franzosi; L Santoro; G Tognoni
Journal:  Circulation       Date:  1997-12-16       Impact factor: 29.690

8.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

Authors:  Y Ohkubo; H Kishikawa; E Araki; T Miyata; S Isami; S Motoyoshi; Y Kojima; N Furuyoshi; M Shichiri
Journal:  Diabetes Res Clin Pract       Date:  1995-05       Impact factor: 5.602

9.  Albuminuria and poor glycemic control predict mortality in NIDDM.

Authors:  M A Gall; K Borch-Johnsen; P Hougaard; F S Nielsen; H H Parving
Journal:  Diabetes       Date:  1995-11       Impact factor: 9.461

Review 10.  Insulin, insulin resistance and platelet function: similarities with insulin effects on cultured vascular smooth muscle cells.

Authors:  M Trovati; G Anfossi
Journal:  Diabetologia       Date:  1998-06       Impact factor: 10.122

View more
  14 in total

1.  Insulin resistance: Is it time for primary prevention?

Authors:  Valentina Mercurio; Guido Carlomagno; Valeria Fazio; Serafino Fazio
Journal:  World J Cardiol       Date:  2012-01-26

Review 2.  Pharmacological strategies to reduce cardiovascular risk in type 2 diabetes mellitus: an update.

Authors:  Marcel M C Hovens; Jouke T Tamsma; Edith D Beishuizen; Menno V Huisman
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Cardiovascular disease in type 2 diabetes: Attributable risk due to modifiable risk factors.

Authors:  John Zeber; Michael L Parchman
Journal:  Can Fam Physician       Date:  2010-08       Impact factor: 3.275

Review 4.  Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.

Authors:  André J Scheen
Journal:  Drugs       Date:  2004       Impact factor: 9.546

5.  Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions.

Authors:  Catherine B Renard; Farah Kramer; Fredrik Johansson; Najib Lamharzi; Lisa R Tannock; Matthias G von Herrath; Alan Chait; Karin E Bornfeldt
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

6.  The cost-effectiveness of pharmacist-led treatment of cardiac risk in patients with type 2 diabetes.

Authors:  Andrew Lowey; Sara Moore; Catherine Norris; David Wright; Jonathan Silcock; Peter Hammond
Journal:  Pharm World Sci       Date:  2007-03-30

7.  Dan-gua fang improves glycolipid metabolic disorders by promoting hepatic adenosine 5'-monophosphate activated protein kinase expression in diabetic Goto-Kakizaki rats.

Authors:  Yuan-long Lan; Su-ping Huang; Xian-pei Heng; Ling Chen; Peng-hui Li; Jing Wu; Liu-qing Yang; Xu-dong Pan; Tong Lin; Xin-ling Cheng; Qing Lin; Si-xin Chen
Journal:  Chin J Integr Med       Date:  2014-08-07       Impact factor: 1.978

Review 8.  Current management strategies for coexisting diabetes mellitus and obesity.

Authors:  Andre J Scheen
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Can a protocol for glycaemic control improve type 2 diabetes outcomes after gastric bypass?

Authors:  Wiebke K Fenske; Dimitri J Pournaras; Erlend T Aasheim; Alexander D Miras; Nicola Scopinaro; Samantha Scholtz; Carel W le Roux
Journal:  Obes Surg       Date:  2012-01       Impact factor: 4.129

10.  Amlodipine versus angiotensin II receptor blocker; control of blood pressure evaluation trial in diabetics (ADVANCED-J).

Authors:  Ryuzo Kawamori; Hiroyuki Daida; Yasushi Tanaka; Katsumi Miyauchi; Akira Kitagawa; Dobun Hayashi; Junji Kishimoto; Shunya Ikeda; Yutaka Imai; Tsutomu Yamazaki
Journal:  BMC Cardiovasc Disord       Date:  2006-10-09       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.